Business
Sol-Gel Reports Third Quarter 2025 Financial Results and Provides Corporate Updates
Sol-Gel intends to pursue high-frequency BCC as an additional indication for its lead drug candidate SGT-610, which, if approved, could at least double the drug’s commercial potentialIn September 2025, Sol-Gel announced Health Canada approval of EPSOLAYSol-Gel signed an additional agreement with Viatris covering Australia and New Zealand for both EPSOLAY and TWYNEO NESS ZIONA, Israel, Nov. 20, 2025 (GLOBE NEWSWIRE) -- Sol-Gel Technologies, Ltd. (NASDAQ: SLGL), a dermatology company, pioneering t
About this update from Viatris Inc.
[{"type":"image","alt":"Sol-Gel Technologies Ltd.","displaySize":"","headline":null,"caption":"Sol-Gel Technologies Ltd.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":61,"url":"https://media.zenfs.com/en/globenewswire.com/cea1966bbf0212443bf12086dfafde1b"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/ojTMH.jAQlcf3jp1GSRJ9w--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTg1O2NmPXdlYnA-/https://media.zenfs.com/en/globenewswire.com/cea1966bbf0212443bf12086dfafde1b","width":300,"height":61}},"lazy":false},{"type":"list","items":[{"val":[{"type":"text","content":"Sol-Gel intends to pursue high-frequency BCC as an additional indication for its lead drug candidate SGT-610, which, if approved, could at least double the drug’s commercial potential","length":183,"tagName":"p"}]},{"val":[{"type":"text","content":"In September 2025, Sol-Gel announced Health Canada approval of EPSOLAY","length":70,"tagName":"p"}]},{"val":[{"type":"text","content":"Sol-Gel signed an additional agreement with Viatris covering Australia and New Zealand for both EPSOLAY and TWYNEO","length":114,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":367,"olType":false},{"type":"text","content":"NESS ZIONA, Israel, Nov. 20, 2025 (GLOBE NEWSWIRE) -- Sol-Gel Technologies, Ltd. (NASDAQ: SLGL), a dermatology company, pioneering treatments for patients with rare and severe skin conditions, today announced financial results for the third quarter ending September 30, 2025, and provided a corporate update.","length":313,"tagName":"p"},{"type":"text","content":"Q3 2025 and Recent Corporate Developments","length":41,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"Sol-Gel’s ongoing Phase 3 clinical trial of SGT-610 (patidegib gel, 2%) for Gorlin syndrome, for which top-line results are expected in the fourth quarter of 2026, has led to growing physician interest in its potential use in patients with severe, high-frequency basal cell carcinoma (BCC). One such case, a non-Gorlin patient in France with a devastating form of high-frequency BCC, was found to have a lesion harboring a PTCH-1 mutation, and Sol-Gel agreed to provide SGT-610 for compassionate use. Sol-Gel plans to supply the drug to additional high-frequency BCC patients with at least one PTCH-1 mutated lesion and is evaluating the initiation of a feasibility study in this ...